Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults
Katherine Mackey, Valerie King, Susan B. Gurley, et al.
Annals of Internal Medicine (2020) Vol. 173, Iss. 3, pp. 195-203
Open Access | Times Cited: 126

Showing 1-25 of 126 citing articles:

The impact of novel coronavirus COVID‐19 on noncommunicable disease patients and health systems: a review
Andrew Y. Chang, Mark R. Cullen, Robert A. Harrington, et al.
Journal of Internal Medicine (2020) Vol. 289, Iss. 4, pp. 450-462
Open Access | Times Cited: 194
Neurobiology of SARS-CoV-2 interactions with the peripheral nervous system: implications for COVID-19 and pain
Amelia J. McFarland, Muhammad Saad Yousuf, Stephanie Shiers, et al.
PAIN Reports (2021) Vol. 6, Iss. 1, pp. e885-e885
Open Access | Times Cited: 111
The Clinical Characteristics and Risk Factors of Severe COVID-19
Jianhua Hu, Yanggan Wang
Gerontology (2021) Vol. 67, Iss. 3, pp. 255-266
Open Access | Times Cited: 109
Disequilibrium between the classic renin-angiotensin system and its opposing arm in SARS-CoV-2-related lung injury
Riccardo Sarzani, Federico Giulietti, Chiara Di Pentima, et al.
AJP Lung Cellular and Molecular Physiology (2020) Vol. 319, Iss. 2, pp. L325-L336
Open Access | Times Cited: 86
Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers with the Risk of Hospitalization and Death in Hypertensive Patients with Coronavirus Disease-19
Rohan Khera, Callahan Clark, Yuan Lu, et al.
medRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 76
First results of the “Lean European Open Survey on SARS-CoV-2-Infected Patients (LEOSS)”
Carolin E. M. Jakob, Stefan Borgmann, Fazılet Duygu, et al.
Infection (2020) Vol. 49, Iss. 1, pp. 63-73
Open Access | Times Cited: 75
The swedish covid‐19 intensive care cohort: Risk factors of ICU admission and ICU mortality
Björn Ahlström, Robert Frithiof, Michael Hultström, et al.
Acta Anaesthesiologica Scandinavica (2021) Vol. 65, Iss. 4, pp. 525-533
Open Access | Times Cited: 72
Proliferation of Papers and Preprints During the Coronavirus Disease 2019 Pandemic: Progress or Problems With Peer Review?
Caitlyn Vlasschaert, Joel Michels Topf, Swapnil Hiremath
Advances in Chronic Kidney Disease (2020) Vol. 27, Iss. 5, pp. 418-426
Open Access | Times Cited: 70
Association of Angiotensin‐Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With the Risk of Hospitalization and Death in Hypertensive Patients With COVID‐19
Rohan Khera, Callahan Clark, Yuan Lu, et al.
Journal of the American Heart Association (2021) Vol. 10, Iss. 13
Open Access | Times Cited: 58
Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS)
Flavio Cadegiani, Andy Goren, Carlos Gustavo Wambier
Medical Hypotheses (2020) Vol. 143, pp. 110112-110112
Open Access | Times Cited: 57
Risk factors for severity of COVID-19 in chronic dialysis patients from a multicentre French cohort
Guillaume Lano, Antoine Braconnier, Stanislas Bataille, et al.
Clinical Kidney Journal (2020) Vol. 13, Iss. 5, pp. 878-888
Open Access | Times Cited: 55
Hypertension and renin-angiotensin system blockers are not associated with expression of angiotensin-converting enzyme 2 (ACE2) in the kidney
Xiao Jiang, James Eales, David Scannali, et al.
European Heart Journal (2020) Vol. 41, Iss. 48, pp. 4580-4588
Open Access | Times Cited: 51
Cardiovascular risk factors and COVID-19 outcomes in hospitalised patients: a prospective cohort study
Didier Collard, Nick S. Nurmohamed, Yannick Kaiser, et al.
BMJ Open (2021) Vol. 11, Iss. 2, pp. e045482-e045482
Open Access | Times Cited: 43
A Drug Safety Evaluation of Dapagliflozin for Diabetic Nephropathies in Patients with Cardiovascular Risk
Aayushi Sood, Aanchal Sawhney, Benjamin Borokhovsky, et al.
Expert Opinion on Drug Safety (2025)
Closed Access
COVID-19: is there a link between the course of infection and pharmacological agents in diabetes?
Tiziana Filardi, Susanna Morano
Journal of Endocrinological Investigation (2020) Vol. 43, Iss. 8, pp. 1053-1060
Open Access | Times Cited: 48
The Yin and Yang of ACE/ACE2 Pathways: The Rationale for the Use of Renin-Angiotensin System Inhibitors in COVID-19 Patients
Loris Zamai
Cells (2020) Vol. 9, Iss. 7, pp. 1704-1704
Open Access | Times Cited: 45
The Effect of Prior Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Treatment on Coronavirus Disease 2019 (COVID-19) Susceptibility and Outcome: A Systematic Review and Meta-analysis
Jiuyang Xu, Yaqun Teng, Lianhan Shang, et al.
Clinical Infectious Diseases (2020) Vol. 72, Iss. 11, pp. e901-e913
Open Access | Times Cited: 41
<p>Role of Renin-Angiotensin System in Acute Lung Injury Caused by Viral Infection</p>
Yanlei Gao, Yue Du, Chao Zhang, et al.
Infection and Drug Resistance (2020) Vol. Volume 13, pp. 3715-3725
Open Access | Times Cited: 36
ACE2 as a Therapeutic Target for COVID-19; Its Role in Infectious Processes and Regulation by Modulators of the RAAS System
Véronique Michaud, Malavika Deodhar, Meghan J. Arwood, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 7, pp. 2096-2096
Open Access | Times Cited: 35
Renin–Angiotensin–Aldosterone System Inhibitors and COVID-19 Infection or Hospitalization: A Cohort Study
Sascha Dublin, Rod Walker, James S. Floyd, et al.
American Journal of Hypertension (2020) Vol. 34, Iss. 4, pp. 339-347
Open Access | Times Cited: 35
Update Alert: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults
Devan Kansagara, Katherine Mackey, Kathryn Vela
Annals of Internal Medicine (2020) Vol. 173, Iss. 3, pp. W66-W66
Open Access | Times Cited: 34
Randomized Prospective Open Label Study Shows No Impact on Clinical Outcome of Adding Losartan to Hospitalized COVID-19 Patients with Mild Hypoxemia
Matthew Geriak, Fadi Haddad, Ravina Kullar, et al.
Infectious Diseases and Therapy (2021) Vol. 10, Iss. 3, pp. 1323-1330
Open Access | Times Cited: 30
Renin‐Angiotensin Aldosterone System Inhibitors and COVID‐19: A Systematic Review and Meta‐Analysis Revealing Critical Bias Across a Body of Observational Research
Jordan Loader, Frances C. Taylor, Erik Lampa, et al.
Journal of the American Heart Association (2022) Vol. 11, Iss. 11
Open Access | Times Cited: 19
Past, present and future of living systematic review: a bibliometrics analysis
Qingyong Zheng, Jianguo Xu, Ya Gao, et al.
BMJ Global Health (2022) Vol. 7, Iss. 10, pp. e009378-e009378
Open Access | Times Cited: 18
COVID-19: A Comprehensive Review on Cardiovascular Alterations, Immunity, and Therapeutics in Older Adults
José Rivera, Natalia Girón, Ester San José
Journal of Clinical Medicine (2023) Vol. 12, Iss. 2, pp. 488-488
Open Access | Times Cited: 11
Page 1 - Next Page

Scroll to top